A 62-year-old man with a history of hypertension and long-standing osteoarthritis is admitted to the hospital with a deep vein thrombosis of the left lower extremity. He is started on a continuous intravenous unfractionated heparin infusion. On admission (day 1), his platelet count is 190,000/μL. On day 6 of hospitalization, his platelet count is found to be 80,000/μL. He is asymptomatic, and his physical examination is notable only for mild swelling of the left leg and a small area of skin necrosis at a recent subcutaneous injection site.
Which of the following is the most appropriate next step in management?
The correct answer is:
B) Discontinue heparin and initiate an argatroban infusion
This patient is presenting with heparin-induced thrombocytopenia (HIT) Type II. HIT is an immune-mediated (IgG) reaction against the Heparin-Platelet Factor 4 (PF4) complex. It typically occurs 5–10 days after starting heparin and is characterized by a drop in platelet count of >50% from baseline. The binding of IgG to the PF4-heparin complex leads to massive platelet activation and the release of prothrombotic microparticles. This creates a highly hypercoagulable state despite the low platelet count. The presence of skin necrosis at injection sites is a highly specific clinical clue for HIT. When HIT is suspected (a high 4T score), the immediate management is to stop all heparin products and start a non-heparin anticoagulant, such as a direct thrombin inhibitor (e.g., argatroban, bivalirudin) or fondaparinux.
Answer choice A: Discontinue heparin and initiate a warfarin loading dose, is incorrect. Warfarin is contraindicated in the acute phase of HIT. Because warfarin inhibits Protein C (an anticoagulant) faster than it inhibits clotting factors, it can cause a transient prothrombotic state that leads to venous limb gangrene in patients with HIT. Warfarin should only be started once the platelet count has recovered to >150,000/μL.
Answer choice C: Discontinue heparin and transfuse one unit of apheresis platelets, is incorrect. Platelet transfusions are generally avoided in HIT. Transfusing platelets may provide more substrate for the formation of the PF4-heparin-IgG complexes, potentially worsening the risk of thrombosis.
Answer choice D: Order a platelet factor 4 (PF4) ELISA and continue heparin pending results, is incorrect. While a PF4 ELISA or a serotonin release assay (SRA) is used to confirm the diagnosis, the discontinuation of heparin must not be delayed while waiting for laboratory results. HIT is a clinical diagnosis, and delay in treatment can lead to life-threatening arterial or venous thrombosis.
Answer choice E: Continue heparin and add aspirin to the regimen, is incorrect. Continuing heparin is dangerous and increases the risk of thrombosis. Aspirin does not address the underlying immune-mediated mechanism of HIT and is insufficient to prevent the catastrophic thrombotic events associated with this condition.
Key Learning Point
Heparin-induced thrombocytopenia (HIT) is a paradoxical condition that causes both low platelets and life-threatening thrombosis. It is caused by IgG antibodies against the PF4-heparin complex. Management requires the immediate cessation of all heparin and the initiation of a direct thrombin inhibitor like argatroban.
